We are currently evaluating over 20 investigational medicines for
more than 20 types of solid tumours and blood cancers. Through our
significant UK clinical trial investment, UK patients will play a key
role in helping us bring a wide range of innovative cancer medicines
into routine use across the NHS. We strive to deliver transformative
therapies that uniquely combine our deep and evolving knowledge in
core areas of biology with our experience in cutting-edge technologies.
Our 6 core areas of biology – apoptosis, targeted cell signaling,
DNA damage, cancer stem cells, immuno-oncology and epigenetics –
evaluate the science of cancer growth and progression.
Our 4 core technologies – antibody drug conjugates (ADC) /
empowered antibodies, dual-variable domain immuno-globulins (DVD) /
bi-specifics, small molecules and T-cell receptors – are being applied
to discover potential cutting-edge cancer therapies with unique biology.